Written by the hosts
Articles
Longer takes on the questions that come up in the clinic and on the show. Each one cites its sources. RSS feed.
-
Article
Menopausal hormone therapy after the WHI: what the follow-up data changed
What the 2002 trial actually tested, what the timing and route data added, how current practice differs from the regimen that made the headlines, and what the FDA changed on the label in 2025 and 2026.
-
Article
Testosterone therapy for women: one supported indication, and prescribing that has outgrown it
What 36 trials show, the one indication the consensus statement supports, and why pellets, injections, and compounded products sit outside the evidence.
-
Article
Female sexual dysfunction: common, undercounted, and rarely one problem
One in four midlife women has a sexual problem that bothers her. Why assessment comes before any product, and what treats the tissue problem underneath many cases.
-
Article
GLP-1 drugs, PCOS, and the fertility effect that needs a conversation
Weight loss can restore ovulation. Women on GLP-1s are conceiving without planning to. What the prescribing conversation has to cover.
-
Article
NAD+ precursors: blood levels rise, outcomes have not followed
What the NR and NMN trials measured, what changed, what didn't, and why there is no test for tissue NAD+.
-
Article
Keto, fasting, and energy balance: positions that changed with the data
Metabolic ward studies on ketogenic and ultra-processed diets, the TREAT trial on time-restricted eating, a metformin trial in older adults, and what each one settled.
-
Article
Prioritizing health interventions: what an N of 1 cannot tell you
Bryan Johnson tests dozens of things on himself at once. Why that design can't assign credit, and what the population data say to fix first.
-
Article
Gray-market peptides, retatrutide, and the difference between a drug and a vial
Retatrutide is unapproved, so every vial sold under that name is unregulated. What the testing shows, and what the evidence for most peptides looks like.
-
Article
Lean mass loss on GLP-1 drugs, and the myostatin drugs trying to prevent it
A quarter to 40 percent of GLP-1 weight loss is lean mass on a DEXA scan. Myostatin blockers preserve it on the scan. So far they have not preserved strength.
-
Article
GLP-1 medications beyond weight loss: how far do the benefits extend?
Heart, kidney, liver, sleep apnea, and two stranger findings. Which GLP-1 benefits are explained by weight loss, and which are not.